Pituitary tumors in patients with MEN1 syndrome

AUTOR(ES)

Syro, Luis V., Scheithauer, Bernd W., Kovacs, Kalman, Toledo, Rodrigo A., Londoño, Francisco J., Ortiz, Leon D., Rotondo, Fabio, Horvath, Eva, Uribe, Humberto

FONTE

Clinics

DATA DE PUBLICAÇÃO

2012

RESUMO

We briefly review the characteristics of pituitary tumors associated with multiple endocrine neoplasia type 1. Multiple endocrine neoplasia type 1 is an autosomal-dominant disorder most commonly characterized by tumors of the pituitary, parathyroid, endocrine-gastrointestinal tract, and pancreas. A MEDLINE search for all available publications regarding multiple endocrine neoplasia type 1 and pituitary adenomas was undertaken. The prevalence of pituitary tumors in multiple endocrine neoplasia type 1 may vary from 10% to 60% depending on the studied series, and such tumors may occur as the first clinical manifestation of multiple endocrine neoplasia type 1 in 25% of sporadic and 10% of familial cases. Patients were younger and the time between initial and subsequent multiple endocrine neoplasia type 1 endocrine lesions was significantly longer when pituitary disease was the initial manifestation of multiple endocrine neoplasia type 1. Tumors were larger and more invasive and clinical manifestations related to the size of the pituitary adenoma were significantly more frequent in patients with multiple endocrine neoplasia type 1 than in subjects with non-multiple endocrine neoplasia type 1. Normalization of pituitary hypersecretion was much less frequent in patients with multiple endocrine neoplasia type 1 than in subjects with non-multiple endocrine neoplasia type 1. Pituitary tumors in patients with multiple endocrine neoplasia type 1 syndrome tend to be larger, invasive and more symptomatic, and they tend to occur in younger patients when they are the initial presentation of multiple endocrine neoplasia type 1.

Documentos Relacionados

• Global gene expression in neuroendocrine tumors from patients with the MEN1 syndrome
• Lack of mutations of exon 2 of the MEN1 gene in endocrine and nonendocrine sporadic tumors
• Variable clinical expression in patients with a germline MEN1 disease gene mutation: clues to a genotype-phenotype correlation
• Localization of the MEN1 gene to a small region within chromosome 11q13 by deletion mapping in tumors.
• Conditional Inactivation of the Men1 Gene Leads to Pancreatic and Pituitary Tumorigenesis but Does Not Affect Normal Development of These Tissues